Recent news highlights Forian's financial performance and business developments, including significant revenue growth and ongoing earnings reports.

• Forian reported a 56% increase in revenue in Q2 2025, reflecting strong growth driven by organic sales and the Kyber acquisition [N6][N7].
• The company has been included in multiple after-hours earnings reports through November 2025, indicating ongoing market attention to its financial results [N1].

Forian's growth is supported by increasing demand for data-driven insights in healthcare and financial services, driven by rising healthcare costs and the need for better understanding of patient and healthcare professional journeys. The company's proprietary data factory and linked longitudinal databases provide unique, actionable information products that address these needs. Expansion into financial services through the Kyber acquisition broadens its addressable market. Continued investments in research and development, sales, and marketing aim to enhance product offerings and customer penetration. The company's multi-year subscription model provides revenue visibility and potential for upselling. Strong liquidity and reduced debt burden support operational flexibility.

Risks include dependency on third-party data vendors, with recent vendor exits and contract terminations posing challenges to data sourcing and product continuity. The company operates in a competitive and rapidly evolving market where larger incumbents may have more resources. Customer concentration risk exists, with a few customers representing significant revenue and accounts receivable portions. The company has reported net losses and may face challenges in achieving sustained profitability. Changes in healthcare regulations, data privacy laws, or market dynamics could impact operations. Integration risks from acquisitions and the need to continuously innovate to maintain differentiation are ongoing concerns.

Forian's competitive strengths include its proprietary cloud-based data factory that integrates and standardizes large-scale, diverse healthcare and consumer data, enabling comprehensive and linked longitudinal patient information. The company's expertise in data management, privacy-compliant analytics, and deep domain knowledge in life sciences and healthcare analytics differentiate its offerings. Its diverse customer base across healthcare and financial services provides multiple perspectives to shape product development. Multi-year subscription contracts and the ability to rapidly deliver flexible, client-centric solutions contribute to customer retention and scalability. The acquisition of Kyber Data Science expanded its market reach into financial services, enhancing its competitive positioning. These factors collectively create barriers to entry and support Forian's market presence.

• Vendor Dependency and Data Licensing Risks: Forian relies on third-party data vendors for key information assets. Recent vendor contract terminations and announced exits from data licensing create uncertainty about the availability and terms of comparable data sources, which could disrupt product offerings.
• Customer Concentration: A small number of customers account for a significant portion of revenue and accounts receivable, exposing the company to risks if these customers reduce or terminate business.
• Profitability and Financial Performance: The company has reported net losses and negative earnings per share, indicating ongoing challenges in achieving profitability despite revenue growth.
• Competitive Market and Innovation: Forian operates in a competitive environment with larger incumbents. Continuous investment in technology, data integration, and product innovation is required to maintain competitive advantage.
• Regulatory and Privacy Compliance: Operating in highly regulated healthcare and financial sectors requires strict compliance with data privacy laws and regulations, which may evolve and impose additional operational burdens.

• Forian Inc. is a provider of data science-driven information and analytics solutions serving the life sciences, healthcare, and financial services industries.
• The company offers subscription and services-based solutions to optimize and measure operational, clinical, and financial performance for customers in life sciences, pharmaceutical services, healthcare payers and providers, and financial services.
• Forian was founded in October 2020 and became publicly traded on Nasdaq under ticker FORA in March 2021.
• The company completed the acquisition of Kyber Data Science LLC in October 2024, expanding its addressable market to financial services, particularly hedge funds investing in healthcare and biotech sectors.
• Forian operates a cloud-based proprietary data factory that processes, enhances, standardizes, and integrates large-scale healthcare and consumer data, including medical, hospital, pharmacy claims, retail point of sale, consumer demographics, and social determinants of health.
• The company provides HIPAA-compliant, linked longitudinal de-identified patient health information databases covering the majority of the U.S. population, updated regularly.
• Forian's information products are largely subscription-based with multi-year contracts, serving both service providers and end customers in healthcare, life sciences, and financial services.
• The company uses deterministic and probabilistic matching techniques on encrypted data to ensure accurate patient matching while maintaining privacy.
• Forian develops Real World Evidence (RWE) and data management solutions to support clinical-grade observational research on safety, efficacy, and therapeutics of traditional and emerging therapies.
• The company has a diverse customer base across healthcare and financial services, including pharmaceutical companies, payers, providers, and institutional investors.
• Forian's revenues for the nine months ended September 30, 2025, were $22.3 million, up from $14.3 million for the same period in 2024, driven by organic growth and the Kyber acquisition.
• Gross profit margin decreased to 55% for the nine months ended September 30, 2025, from 66% in the prior year period, due to higher information licensing and processing expenses.
• Net loss for the year ended December 31, 2025, was $2.87 million, with basic and diluted net loss per share of $0.09.
• The company had cash and cash equivalents of approximately $12.9 million and short-term investments of $18.6 million as of December 31, 2025, with a current ratio of 2.97 and cash ratio of 2.2.
• Forian's operations are primarily in the United States, with 95% of sales in 2025 from the U.S., and small percentages from Australia and Great Britain.
• The company had one customer representing 11.2% of revenue in 2025 and one customer representing 34.8% of accounts receivable at year-end 2025.
• Forian has reduced litigation settlements and related expenses significantly in 2025 compared to 2024.
• The company has been investing in sales and marketing, research and development, and strategic partnerships to grow its business.
• Forian completed a redomiciliation from Delaware to Maryland effective January 9, 2026, with no impact on business operations or contracts.
• The company has retired convertible notes and reduced interest expenses in 2025.
• Adjusted EBITDA increased to $840,408 for the year ended December 31, 2025, from $489,134 in 2024.
• Recent news highlights include a 56% revenue increase in Q2 2025 and ongoing earnings reports through November 2025.